Ikarian Capital’s Autolus Therapeutics AUTL Stock Holding History

Ikarian Capital’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-262,694	Closed	-$1.69M	–	144
2023 Q4	$1.69M	Hold	262,694	–	–	0.16%	90
2023 Q3	$612K	Buy	262,694 +2,607	+1%	+$7.43K	0.07%	108
2023 Q2	$619K	Hold	260,087	–	–	0.1%	94
2023 Q1	$479K	Hold	260,087	–	–	0.11%	95
2022 Q4	$494K	Hold	260,087	–	–	0.12%	59
2022 Q3	$556K	Sell	260,087 -62,130	-19%	-$184K	0.11%	81
2022 Q2	$912K	Sell	322,217 -50,000	-13%	-$152K	0.17%	82
2022 Q1	$1.55M	Sell	372,217 -172,602	-32%	-$726K	0.2%	80
2021 Q4	$2.83M	Hold	544,819	–	–	0.42%	53
2021 Q3	$3.57M	Sell	544,819 -811,229	-60%	-$5.12M	0.25%	88
2021 Q2	$9M	Buy	1,356,048 +100,000	+8%	+$621K	0.73%	38
2021 Q1	$7.2M	Buy	+1,256,048	New	+$9.3M	0.24%	92

Other funds holding AUTL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ikarian Capital's AUTL Position: Q1 2024 in Review

Ikarian Capital sold out of Autolus Therapeutics (AUTL) in Q1 2024, closing a stake of 262,694 shares — an estimated $1.69M sold.

Ikarian Capital first reported a position in AUTL in Q1 2021 and held it in 12 quarters. The position peaked at $9M in Q2 2021. 121 funds tracked by Wall St. Rank hold AUTL as of Q1 2024.

Ikarian Capital reported no remaining Autolus Therapeutics position as of Q1 2024 after selling out during the quarter.
Ikarian Capital sold 262,694 Autolus Therapeutics shares in Q1 2024, an estimated $1.69M.
Ikarian Capital first reported a position in Autolus Therapeutics in Q1 2021 and held it in 12 quarters.
Ikarian Capital's Autolus Therapeutics position peaked at $9M in Q2 2021.
121 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2024.

Based on Ikarian Capital's 13F filing for Q1 2024, filed 15 May 2024.